

09 807579

PCT/EP 99 / 07755

Europäisches
PatentamtEur pean
Patent OfficeOffice eur péen
des brevets

EP 99 / 7755

4

REC'D 29 NOV 1999

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

98119409.5

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

I.L.C. HATTEN-HECKMAN

DEN HAAG, DEN
THE HAGUE,
LA HAYE, LE

22/11/99

THIS PAGE BLANK (USPTO)



**Eur päisches
Patentamt**

**Eur pean
Patent Office**

**Office eur péen
des brevets**

**Blatt 2 der Bescheinigung
Sheet 2 of the certificate
Page 2 de l'attestation**

Anmeldung Nr.:
Application no.:
Demande n°: **98119409.5**

Anmeldetag:
Date of filing: **14/10/98**
Date de dépôt:

Anmelder:
Applicant(s):
Demandeur(s):
**Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
69120 Heidelberg
GERMANY**

Bezeichnung der Erfindung:
Title of the invention:
Titre de l'invention:
Parvovirus-vectors and their use

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat:	Tag:	Aktenzeichen:
State:	Date:	File no.
Pays:	Date:	Numéro de dépôt:

Internationale Patentklassifikation:
International Patent classification:
Classification internationale des brevets:
C12N15/86, C12N5/10, A61K48/00

Am Anmeldetag benannte Vertragsstaaten:
Contracting states designated at date of filing: AT/BE/CH/CY/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE
Etats contractants désignés lors du dépôt:

Bemerkungen:
Remarks:
Remarques:

THIS PAGE BLANK (USPTO)

13. Oktober 1998

EPO - Munich
22

14. Okt. 1998

Parvovirus Vectors and Their Use

The present invention relates to parvovirus vectors and systems containing the same. Furthermore, this invention concerns a method of producing the parvovirus vectors and their use.

Parvovirus designates a genus of the virus family Parvoviridae. The parvovirus genus comprises a number of small, icosaedric viruses that can replicate in the absence of a helper virus. Parvovirus contains a single-stranded DNA having a size of about 5.000 bp. At the 3' and 5' ends of the DNA there is one palindromic sequence each. The DNA codes for two capsid proteins, VP1 and VP2, as well as for two regulatory non-structure proteins, NS-1 and NS-2. The expression of the latter proteins is controlled by a promoter, P4, while a promoter, P38, which is transactivated by NS-1, is responsible for the expression of the capsid proteins.

Parvoviruses are usually well-tolerated by populations of their natural host, in which they persist without apparent pathological signs. This is due to both the protection of foetuses and neonates by maternal immunity, and the striking restriction of parvovirus replication to a narrow range of target proliferating tissues in adult animals. This host tolerance concerns especially rodent parvoviruses, for example the minute virus of mice (MVM) and H-1 virus in their respective natural hosts, namely mice and rats. In addition, humans can be infected with the latter viruses, without any evidence of associated deleterious effects from existing epidemiological studies and clinical trials. On the other side, it is known that certain parvoviruses, and especially rodent parvoviruses, are both oncotropic, i.e. accumulate preferentially in neoplastic versus normal tissues, and oncosuppressive, i.e. have a tumorsuppressive effect towards tumor cells, in various animal models. At least part of the oncosuppressive effect is thought to be due to a direct oncolytic action mediated by the parvoviral NS1 product. This oncosuppressive effect was also demonstrated against human tumor cells transplanted in recipient animals.

13. Oktober 1998

- 2 -

This could be utilized for treating tumors. For this purpose, it is, however, desirable to modify parvoviruses in well-calculated fashion, i.e. give them new properties, e.g. to express therapeutic genes, and provide a great quantity thereof. The former appears to be possible by a parvovirus vector in which parvovirus DNA converted into a double strand is ligated with a vector DNA and the parvovirus DNA region coding for the capsid proteins is replaced by exogenous DNA. Following the transfection of parvovirus-permissive cells, such a parvovirus vector is subjected to the excision of the parvovirus DNA and its amplification and packaging, respectively, into parvoviruses (cf. Russell, S.J. et al., Journal of Virology, 1992, 2821-2828). However, the yield of parvovirus DNA which is amplified and packed, respectively, is unsatisfactory.

Therefore, it is the object of the present invention to provide a composition by which a great quantity of packed, optionally modified, parvovirus DNA can be produced.

According to the invention this is achieved by the subject matters defined in the claims.

Thus, the subject matter of the present invention relates to a parvovirus vector having a parvovirus DNA which can be excised from the vector DNA in a parvovirus-permissive cell, the parvovirus DNA having a left terminus which comprises a minimal parvovirus origin of replication.

The present invention is based on the applicant's finding that in parvovirus-permissive cells a parvovirus present in a parvovirus vector can be excised therefrom and be replicated when its left terminus comprises a minimal parvovirus origin of replication.

The expression "parvovirus-permissive cell" comprises any cells in which a parvovirus genome can be amplified and packed into infectious viral particles. Examples of such cells are established cell lines of mice, e.g. A9 cells,

13. Oktober 1998

- 3 -

of human origin, e.g. NB-E-, NB324K, 293 T cells, and of monkey cells, e.g. COS cells.

5 The expression "left terminus" refers to the 3' end of a parvovirus DNA available as a double strand. As mentioned above, a parvovirus DNA is usually single-stranded. However, such a DNA can be converted into a double strand by common methods. In this form it is then ligated directly or indirectly, e.g. via a linker, with a conventional vector DNA. According to the invention, the left terminus of the parvovirus DNA includes a minimal parvovirus origin of replication. For the definition of a minimal parvovirus origin of replication, reference is made to Cotmore and Tattersall, EMBO J. 13, 1994, 4145. It comprises the consensus sequence of an NS-1 nicking site. The consensus sequence is preferably CTWWTCA, W representing any nucleotide. . For the provision of a minimal parvovirus origin of replication at the left terminus of the parvovirus DNA it is favorable to extend the left terminus by an inverted repeat of the unique sequence located immediately downstream from the 3' terminal palindrome of the parvovirus DNA. A person skilled in the art is familiar with processes necessary for this purpose. Reference is made to Maniatis et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982, by way of supplement.

As far as the "right terminus", i.e. the 5' end, of the parvovirus DNA available as a double strand is concerned, it may be the naturally occurring 5' terminus of a parvovirus DNA. It may be favorable for the 5' terminus to have internal replication sequences (IRS). They are found e.g. in the RsaIA (4431-4579) and RsaIB (4579-4662) fragments of the DNA of the parvovirus MVMp (cf. Tam and Astell, Virology 193, 1993, 812-824, and J. Virol. 68, 1994, 2840-2848).

30 In a preferred embodiment, the parvovirus DNA originates from a mammalian parvovirus, particularly a rodent parvovirus, very especially from MVM or H-1. Both rodent parvoviruses are described in the literature (cf. Astell et al.; J. Virol. 57, 1986, 656-669; Rhode and Paradiso, J. Virol. 45, 1983, 173-184; Faisst

13. Oktober 1998

- 4 -

et al., J. Virol. 69, 1995, 4538-4543). It may be favorable for the parvovirus DNA to comprise a combination of DNA sequences of various parvoviruses, e.g. of mammalian parvoviruses, especially rodent parvoviruses, very especially MVM, H-1 KRV and/or LuIII. It may be particularly advantageous for the parvovirus DNA to originate from H-1 and for its left terminus to comprise a minimal parvovirus origin of replication of MVM.

According to the invention the parvovirus DNA may include an exogeneous DNA. This DNA may be inserted such that it can be expressed. For this purpose, it is favorable for it to be under the control of the parvovirus promoter P38, i.e. it partially or fully replaces the parvovirus DNA region coding for the capsid proteins. An exogeneous DNA is understood to mean any DNA. This may be e.g. an expression element such as a promoter or an enhancer, or a DNA coding for a diagnostic or therapeutic polypeptide. The latter polypeptide is particularly a cytokine, such as a lymphokine, an interleukin or a "colony stimulating factor", a chemotactic polypeptide, such as a polypeptide suitable for attracting monocytes, e.g. MCP-1, or a toxin.

According to the invention the parvovirus DNA may also include deletions of specific parts, e.g. regulatory elements, such as promoters, promoter elements, or genes coding for non-structural proteins. Instead of these deletions an exogenous DNA may be inserted.

Parvovirus vectors of choice fulfilling above conditions are exemplified below with pdBMVp, pMVM + , pH1, pH1 Δ 800, pH1 Δ 800MCP-1, pH1 Δ 800MCP-1 Δ 3' and pH1 Δ 800hIL2 (cf. examples 1-3). These parvovirus vectors have been deposited at DSMZ (Deutsche Sammlung für Mikroorganismen und Zellkulturen) on July 9, 1998 under the following DSM numbers: pdBMVp (DSM 12300), pMVM + (DSM 12301), pH1 Δ 800 MCP-1 (DSM 12302), pH1 Δ 800hIL2 (DSM 12303), pH1 Δ 800MCP-1 Δ 3' (DSM 12304), pH1 Δ 800 (DSM 12305), pH1 (DSM 12306).

13. Oktober 1998

- 5 -

According to the invention the parvoviral genome produced from a parvovirus vector may be packaged in the form of a parvoviral particle. Such a particle is designated to as parvovirus particle and obtainable by common methods. If the parvovirus vector harbors no substitution in essential parvovirus coding and regulatory sequences, it will be an obvious choice to transfect the parvovirus vector only in cells which are parvovirus permissive. Examples of such cells are SV 40-transformed monkey kidney cells, such as COS, or SV40-transformed human kidney cells, such as NB-E, NB324K and 293T, e.g. 293T/17 and A9 mouse cells. Parvovirus vector and parvoviral particles may then be isolated from the cells.

If the parvovirus vector lacks part or all of the parvovirus DNA region coding for the parvovirus capsid proteins, it will be necessary to transfect the parvovirus vector in parvovirus-permissive cells which simultaneously express the capsid proteins of a parvovirus when parvoviral particles have to be produced. The cells may be the above cells which are transfected with a helper plasmid that permits the expression of the capsid proteins of a parvovirus. The VP proteins may also be provided by capsid genes stably integrated in the cellular genome and constitutively or inducibly expressed.

As far as the sequence coding for the structural proteins (VP) are concerned, it was discovered that certain viral sequences located in the 3' part of the genes coding for the VP proteins should be maintained in the parvovirus vector in order to obtain high titers of parvoviral particles. These sequences are not or only barely affected by deletions in the VP coding region that do not exceed approximately 800 nt starting from the ATG corresponding to the translation initiation site of the viral VP2 protein. According to the invention these sequences should be maintained if high titers of parvoviral particles have to be produced.

It may be favorable for the helper plasmid mentioned above to contain an SV40 or polyoma virus origin of replication and for the cells to express an SV40 or

13. Oktober 1998

- 6 -

polyoma large T antigen. Examples of such helper plasmids are p[BK]CMV-VP and p[BK]P38-VP that are based on pBK-CMV (Stratagene) and encode H-1 capsid proteins. The helper plasmids pCMVVP(MVM) and pP38VP(MVM) are based on the vector pcDNA1/Amp (Invitrogen Corporation) and can provide MVMp capsid proteins for packaging. In these constructs, the parvovirus capsid protein-coding sequences are under the transcriptional control of the human cytomegalovirus (CMV) immediate early promoter (p[BK]CMV-VP, pCMVVP(MVM)) or the P38 parvovirus promoter (p[BK]P38-VP, pP38VP(MVM)). COS and 293 T cells can be mentioned as examples of cells which express an SV40 large T antigen. The transfection of cells expressing an SV40 large T antigen with a helper plasmid containing an SV40 origin of replication usually results in the transient expression of parvovirus capsid proteins at an extremely high level.

Furthermore, a stable expression of parvovirus capsid proteins may be advantageous. Suitable for this purpose are also the above cells, particularly 293 T cells, which are stably transfected with a helper plasmid, such as a derivative of the above-mentioned helper plasmids. It may be appropriate for the cell to have stably inserted VP coding genes under control of an inducible promoter (in particular the parvoviral P38 promoter) or a strong constitutive promoter (in particular the human or mouse CMV immediate early promoter). Above cells engineered so as to sustain a stable expression of parvovirus capsid proteins also represent a subject matter of the present invention. A person skilled in the art is familiar with transfection methods by which the transient or stable expression of parvovirus capsid proteins is obtained. Cells which permit a stable expression of the capsid proteins of a parvovirus also represent a subject matter of the present invention.

Another subject matter of the present invention relates to a system comprising an above parvovirus vector and a cell expressing capsid proteins of parvovirus. It is favorable for the expression of the capsid proteins to be controlled by a helper plasmid containing an SV40 origin of replication and for the cell to express an SV40 large T antigen. It may also be advantageous for the cell to

13. Oktober 1998

- 7 -

stably express the capsid proteins of parvovirus, it being preferred when the DNA coding for the capsid proteins is controlled by the P38 parvovirus promoter.

- 5 Parvovirus vectors according to the invention distinguish themselves in that they permit higher levels of amplification of the parvovirus genomes that are excised from the parvovirus vectors. Moreover, the above-mentioned packaging cell lines (e.g. monkey COS, 293T) are highly susceptible to transfection by the convenient and cost-sparing Calciumphosphate coprecipitation techniques or DEAE-DEXTRAN and allow the use of shuttle helper plasmids of the type discussed above. The combination of the described changes in parvovirus vector and packaging systems greatly improves the yields of parvovirus vector (parvovirus DNA insert) production giving up to 1000 times higher titers of infectious parvoviral particles as compared with the conventional parvovirus vectors packaging system, in particularly those described in Russell, S.J. et al., above. This represents a great advantage, particularly as regards time and costs. Parvovirus vector and parvoviral particles produced according to the invention are suitable for gene therapy in the best possible way. Especially a gene therapy is indicated in the case of tumor or viral diseases because of the possibility of expressing the cytotoxic viral protein NS-1 together with a therapeutic polypeptide, particularly cytokines.
- 15
- 20

The below examples explain the invention.

- 25 **Example 1: Construction of the parvoviral vectors pdBMVp, pMVM+ and pH1 and the derivative empty parvovirus vector pH1Δ800 according to the invention**

- 30 Construction of pdBMVp: The vector pdBNco was constructed by putting *Nco*I linkers into the *Sma*I site of pUC19 and then ligating the *Nco*I dimer bridge (dB) fragment from pLEB711 [Cotmore, S.F. and Tattersall, P. (1992). Journal of Virology 66; 420-431] into the resulting *Sma*I site. pdBNco was then linearized

13. Oktober 1998

- 8 -

with *Bam*HI (in the pUC polylinker) and then partially digested with *Pme*I. The ends of these partials were filled in and ligated together, allowing the isolation of pdB-BP-drop, which is pdBNco deleted for the sequence between the *Bam*HI site in the polylinker and the *Pme*I site in the insert nearest to *Bam*HI. This procedure destroyed these *Bam*HI and the *Pme*I sites, leaving the remaining *Pme*I in the insert unique. pdB-BP-drop was then digested with *Sap*I (in the plasmid) and *Xba*I (in the polylinker), filled in, and ligated back together to form pdB-SX-drop, just to remove a non-essential part of the plasmid, and to render several sites within the final construct unique. To obtain the final construct, the *Pme*I to *Aat*II fragment of pdB-SX-drop was replaced with the *Pme*I to *Aat*II fragment of the second generation infectious clone pMVM [Gardiner, E.M. and Tattersall, P.(1988) Journal of Virology 62: 1713-1722]. The resulting third generation plasmid is the "dimer bridge" super-infectious clone of MVMp called pdBMVp.

pMVM+ is a spontaneous deletion mutation of pdBMVp missing the MVMp sequences from 4985-5003.

ph1 (infectious clone) consists of the *Sal*I-*Nde*I fragment of pSR19 [Faisst et al., J. Virol. 69, 4538-4543 (1995)] containing nt 11 to nt 5110 of H-1 (EMBL GenBank#X01457) into the *Nde*I and *Sal*I sites of pUC19 from which the *Hind*III site had been destroyed. ph1 was constructed by replacing the 1386 bp *Hae*III fragment of ph1 by the corresponding fragment of MVM+ containing the dimer bridge, P4 promotor and 995 nt of MVM NS1/NS2 coding region.

Thus the parvovirus DNAs carried by pdBMVp, pMVM+ and phH1 contain a MVM-minimal origin of replication at the left (3') terminus of the viral genome and are able to provide high amounts of infectious virus upon transfection of monkey COS or 293 T cells as compared with conventional parental vectors (pMVM and pSR19) and those described in Russ II et al. (1992) which are deprived of a full minimal origin of DNA replication (for instance pMM984). pdBMVp, pMVM+ and phH1 infectious clones are the starting material for the

13. Oktober 1998

- 9 -

construction of parvovirus DNA containing or not foreign DNA.

For the convenient insertion of transgenes under control of the parvovirus H-1 P38 promoter, a modified parvovirus DNA was constructed from the DNA pH1, whereby the VP2 translation initiation signal (ATG) and approximately 800 nt from the downstream VP sequence were eliminated and replaced by an ochre termination signal (TAA) in frame with VP1, followed by a multiple sequence (CGC CTA GTA CTC GAG CTC TTC GAA GCG GCC GCG GAT CCG ATC GCC TAG GCC CGG GTA TCG AT). More precisely, starting from position nt 2791 of pH1 [numbering according to EMBL/GenBank#X01457, Rhode and Paradiso, (1983). Journal of Virology 45, 173-184], 806 nucleotides were replaced by the above described termination signal and multiple cloning site. This created the empty parvovirus vector pH1 Δ 800 according to the invention.

Example 2: Construction of parvovirus vectors pH1 Δ 800MCP-1 and pH1 Δ 800MCP-1 Δ 3' according to the invention

The human JE (MCP-1) cDNA [Rollings et al., Mol.Cell.Biol. 4687-4695 (1989)] was obtained from the American Type Culture Collection (ATCC, nr. 61365). The full length cDNA was isolated by PCR using a forward primer containing a *Hind*III site (CTAAGCTTAGCATGAAAGTCTCTGCC) and a reverse primer with an incorporated *Hpa*I site (GCGTTAACTAATAGTTACAAAATAT). After digestion with *Sac*I and *Hpa*I, the 701 bp PCR fragment was cloned between the *Sac*I and the *Sma*I restriction sites of pH1 Δ 800, to create pH1 Δ 800MCP-1 according to the invention. The MCP-1 cDNA deprived of its 3' untranslated region (3'UTR) was amplified using the same forward primer and the reverse primer (GCGTTAACTTCAAGTCTTCGGAGTT) with an incorporated *Hpa*I site. After digestion with *Sac*I and *Hpa*I, the 355 bp PCR fragment was cloned between the *Sac*I and *Sma*I restriction sites of pH1 Δ 800 to generate pH1 Δ 800MCP-1 Δ 3'. Both vector DNAs achieve high titers of parvoviral particles when parvoviral capsid proteins are simultaneously expressed from a helper plasmid as described above.

13. Oktober 1998

- 10 -

Exempl 3: Construction of the parvovirus vectors pH1Δ800HIL2 according to the invention

5 The cDNA coding for human IL2 deprived of its 3' untranslated region was excised from the plasmid M13TG5317 (Transgene, Strasbourg) by hydrolysis with *Sa*I, and inserted in the *Sa*I site of pBluescript SK+ (EMBL/Gen-Bank#X52325) giving pHIL2. pHIL2 was cut with *Xho*I and *Bam*HI and the 539 bp fragment was inserted in the *Xho*I and *Bam*HI hydrolysed empty parvovirus vector pH1Δ800 (see example 1), generating the human IL2 expressing parvovirus vector pHΔ800hIL2, from which parvovirus DNA and parvoviral particles
10 can be produced.

Example 4: Production of high-titer stocks of parvoviral particles

15 The genes coding for the structural proteins of parvovirus H-1 or MVMP under control of the genuine parvoviral promoter P38 or the human CMV immediate early promoter are cloned in the shuttle vector pBK-CMV (Stratagene) or pcDNA1/Amp (Invitrogen), both containing an SV40 origin of replication, this gives rise to the helper plasmids p[BK]P38-VP and p[BK]CMV-VP, which provide
20 H-1 capsid proteins, or pCMVVP(MVM) and pP38VP(MVM), which provide MVMP capsids. 293T cells are transfected with one of the VP-expressing helper plasmids and one of the above parvovirus vectors according to the invention. Parvoviral particles are recovered from the cells and titered by a filter hybridization technique [Russell et al., 1992]. From the parvovirus vectors described in
25 examples 2-3, titers of up to 10^8 replication units of parvoviral particles (described in the examples 2-3) per ml of crude extract can be obtained in this way.

13. Oktober 1998

- 11 -

EPO - Munich
22

14. Okt. 1998

Claims:

1. A parvovirus vector having parvovirus DNA excisable from the vector DNA in a parvovirus-permissive cell, wherein the parvovirus DNA has a left terminus which comprises a parvovirus minimal origin of replication.
2. The parvovirus vector according to claim 1, characterized in that the right terminus of the parvovirus DNA comprises internal replication sequences.
3. The parvovirus vector according to claim 1 or 2, characterized in that the parvovirus minimal origin of replication comprises the consensus sequence of an NS1 nicking site, particularly CTWWTCA.
4. The parvovirus vector according to any one of claims 1 to 3, characterized in that the parvovirus DNA originates from a mammalian parvovirus.
5. The parvovirus vector according to any one of claims 1 to 3, characterized in that the parvovirus DNA is a rodent parvovirus.
6. The parvovirus vector according to claim 5, characterized in that the rodent parvovirus is MVM or H-1.
7. The parvovirus vector according to any one of claims 1 to 3, characterized in that the parvovirus DNA comprises a combination of DNA sequences of various parvoviruses.
8. The parvovirus vector according to claim 7, characterized in that the parvovirus DNA originates from H-1 and its left terminus comprises a minimal parvovirus origin of replication of MVM.
9. The parvovirus vector according to any one of claims 1 to 8, characterized in that the parvovirus DNA region coding for the capsid protein

13. Oktober 1998

- 12 -

is partially or fully replaced by an exogenous DNA.

- 5
10. The parvovirus vector according to claim 9, characterized in that the exogenous DNA codes for a polypeptide usable in a treatment.
11. The parvovirus vector according to claim 10, characterized in that the polypeptide is a cytokin or a toxin.
- 10 12. The parvovirus vector according to claim 11, characterized in that the cytokin is a chemotactic polypeptide.
13. The parvovirus vector according to claim 12, characterized in that the chemotactic polypeptide is MCP-1.
- 15 14. The parvovirus vector according to any one of claims 1 to 13, characterized in that it is present as parvoviral particle.
15. A system comprising the parvovirus vector according to any one of claims 9 to 13 and a cell expressing the capsid proteins of parvovirus.
- 20 16. The system according to claim 15, characterized in that the expression of the capsid proteins is controlled by a helper plasmid containing an SV40 origin of replication and the cell expresses an SV40 large T antigen.
- 25 17. The system according to claim 15, characterized in that the DNA coding for the capsid proteins is under the control of the parvovirus promoter P38.
- 30 18. A method of producing the parvoviral particle according to claim 14, comprising the transfection of a parvovirus-permissive cell with a parvovirus vector according to any one of claims 9 to 13, the cell expressing the capsid proteins of a parvovirus, and the isolation of the parvoviral particle.

13. Oktober 1998

- 13 -

19. Use of the parvovirus vector according to any one of claims 9 to 14 for gene therapy.
20. Use according to claim 19, characterized in that the gene therapy is carried out in the case of tumor diseases.

5



13. Oktober 1998

- 14 -

Abstract of the Disclosure

EPO - Munich
22

14. Okt. 1998

Parvovirus Vectors and Their Use

- 5 This invention relates to a parvovirus vector having a parvovirus DNA excisable from the vector DNA in a parvovirus-permissive cell, the parvovirus DNA having a left terminus which comprises a parvovirus minimal origin of replication, and a system comprising the parvovirus vector. Furthermore, this invention concerns a method of producing the parvovirus vector, parvoviral particles as well as their use.

THIS PAGE BLANK (USPTO)